Adaptive Adjuvant Sintilimab Therapy Guided by MRD in II-IIIB Stage NSCLC Patients With Non-pCR Pathological Response After Neoadjuvant Immunotherapy Combined With Chemotherapy: a Prospective, Multi-center, Single-arm, Phase II Trial
Latest Information Update: 21 Aug 2025
At a glance
- Drugs Sintilimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ADAPT Lung
Most Recent Events
- 21 Aug 2025 New trial record